Medical Properties Trust, Inc. (MPT) Q4 2014 Earnings Report, Transcript and Summary

Good day, ladies and gentlemen and welcome to the Quarter Four 2014 Medical Properties Trust Earnings Conference Call. My name is Kathy and I will be your operator for today. At this time, all participants are in a listen-only mode. We will conduct a question-and-answer session towards the end of this conference. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Charles Lambert, Managing Director. Please proceed, sir.

Good morning. Welcome to the Medical Properties Trust conference call to discuss our fourth quarter and full year 2014 financial results. With me today are Edward K. Aldag, Jr., Chairman, President and Chief Executive Officer of the company and Steven Hamner, Executive Vice President and Chief Financial Officer. Our press release was distributed this morning and furnished on Form 8-K with the Securities and Exchange Commission. If you did not receive a copy, it is available on our website at www.medicalpropertiestrust.com in the Investor Relations section. Additionally, we are hosting a live webcast of today’s call, which you can access in that same section. During the course of this call, we will make projections and certain other statements that may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause our financial results and future events to differ materially from those expressed in or underlying such forward-looking statements. We refer you to the company’s reports filed with the Securities and Exchange Commission for a discussion of the factors that could cause the company’s actual results or future events to differ materially from those expressed in this call. The information being provided today is as of this date only and except as required by Federal Securities laws, the company does not undertake a duty to update any such information. In addition, during the course of the conference call we will describe certain non-GAAP financial measures, which should be considered in addition to, and not in lieu of, comparable GAAP financial measures. Please note that in our press release, Medical Properties Trust has reconciled all non-GAAP financial measures to the most directly comparable GAAP measures in accordance with Reg G requirements. You can also refer to our website at www.medicalpropertiestrust.com for the most directly comparable financial measures and related reconciliations. I will now turn the call over to our Chief Executive Officer, Ed Aldag.

Thank you, Charles and thanks all of you for joining us today for our fourth quarter year end 2014 Medical Properties Trust earnings call. 2014 was a fantastic year for MPT, not only did our current portfolio perform well, which I will go into more details in a few moments, but we invested or committed to invest almost $1.4 billion in 2014. This increased our total asset base by approximately 45% compared to the prior year end. With this increase in asset base, we greatly strengthened our portfolio through geographic tenant and property type diversification. As you would expect with this type of growth, our revenue and FFO grew at 29% and 10% per share respectively during 2014. Steve will give you more details in just a few minutes. We also expect to have further significant FFO growth per share in 2015. It is important to note that S&P raised our overall credit rating and upgraded our senior notes to investment grade during the fourth quarter. Shortly after we announced in October the nearly $1 billion acquisition of the MEDIAN Kliniken properties, MPT senior management embarked on a month-long series of meetings visiting with existing investors and new investors to update them on MPT. When we announced the MEDIAN acquisition, our stock price was $13.49 per share. By the time, we finished our month-long series of meetings, the stock price had risen almost 6%. In early January, we completed the largest equity offering in the company’s history and the offering priced at $14.50 per share, a 1.8% premium from the announcement of the offering. The success of this offering is a testament to the success we had in 2014 and the strength of the MPT portfolio. Now, I would like to just briefly update you on some of our properties…

Thank you, Ed. Normalized FFO per share for the fourth quarter was an expected $0.28, a 17% year-over-year increase compared to 2013. For the full year, we increased FFO per share by more than 10% to $1.06. We have not made any acquisitions in 2015 and yet our existing our portfolio is set again to deliver strong double-digit growth in per share results for 2015. We will address our outlook in just a few moments. Included in NAREIT defined FFO is an adjustment for gain of about $2.9 million on the sale of our La Palma Community Hospital to Prime Healthcare. As a reminder to you Prime has the option to repurchase and substitute one hospital each year for purposes of contributing the hospital to its not-for-profit affiliate Prime Healthcare Foundation and MPT does not presently own any of the facilities operated by the Prime Foundation. Further adjustments to FFO to result in normalized FFO include the following. Acquisition cost of $18.5 million including major line items for, first $3.9 million in real estate transfer taxes related to the three rehab hospitals we acquired from RHM along with related legal and other transaction costs. Second, $9.5 million for the early breakage of contracts to hedge $532 million equivalent of our euro exposure between the time we executed the contracts to acquire the MEDIAN assets and the closing of the transaction. And lastly approximately $5.1 million in other transaction costs primarily legal, other professional fees and diligence cost mostly for the MEDIAN transaction. Other adjustments to arrive at normalized FFO are $1.4 million in contingent financing fees, legal and other costs related to a $225 million loan commitment from our bank group that was terminated subsequent to the issuance of common shares in January and finally $1.9 million in the write-off…

[Operator Instructions] The first question comes from the line of Karin Ford, KeyBanc Capital Markets.

Hi, good morning.

Good morning, Karin.

First, if I could start just with the adjustments to the run-rate that you mentioned. Can you just quantify the impact of the lower interest rates and the exchange rates? And just talk about what exposure you have to changing exchange rates going forward?

Okay, that’s two questions. I will take them in sequence. Everything is fungible. We have adjusted the range by $0.02 on the low end and a $0.01 on the high end. So, any single one of the components we mentioned whether its exchange rates or interest cost or the cost of the equity that we issued really we haven’t quantified and put them in separate buckets. All of those components are subject to further assumptions about timing and how much, so we haven’t quantified. I am not sure there is relevance to us to quantify how much of the penny adjustment could possibly come from one component versus another. With respect to exposure to exchange rates, we are certainly exposed to the market. Keep in mind that it’s only an economic exposure to the extent that we bring euros home convert them to dollars to either pay debt pay dividends or whatever. Now, from a GAAP perspective, it’s not treated that way, but we are in the process now of modeling out just that how much of our future expected rental income in euros will be used to pay for euro-denominated debt to reinvest in euro-denominated assets and then how much to bring home reconvert to dollars. That last net amount is what we will then consider placing short-term rolling hedges on to smooth out the exchange rate impact. Remember, these are at least 27-year assets and there is obviously no way you can hedge out that, that far. In fact, hedging out 18 to 36 months is generally considered probably the longest term that you can do that efficiently and that’s what we would plan to do is have a rolling series of hedges of 18 to 36 months.

Okay, thanks for that. I think you had estimated previously that you thought cost of secured debt would be around 3.5% and unsecured might be around 5%. Do you have updated estimates as to what those might be today?

They have only come down, Karin, particularly the unsecured debt. As Ed mentioned and you certainly know, our debt has been upgraded to investment grade. So that in and of itself has brought in our unsecured rate somewhat along with the overall interest rate environment, and in particular, the euro-denominated interest rate environment. So whereas our earlier estimates of unsecured debt costing as much as 5% has probably come in at least 100 and frankly probably more than 100 basis points. So, we would expect to issue something between 3% and 4%. On the secured side, that depends a lot on other terms, including loan-to-value, including the level of securitization or collateralization, I should say. But there again, we think that has come in much less, but probably a meaningful 25 basis points.

Thanks for that. Can you just characterize the pipeline? I appreciate the $600 million to $800 million number that you gave us you are thinking about in 2015. Just talk about what the composition is of the pipeline that you are looking at in terms of asset class, geography, portfolios or individual deals?

Karin, the vast majority of that will continue to be acute care hospitals. Almost all of our pipeline that we are currently working on with the exception of some facilities that we are looking at with our existing customers, are all acute care hospitals. From a geographic standpoint right now, with having roughly 75% of it here in the U.S., as we have said on the last couple of calls, we do expect that the amount of properties that are in Europe will go up on a temporarily basis from maybe as much as 35%, but we will typically run in the 70% to 30% range.

Okay, thanks. And then just last question, I know it’s still relatively early, but do you have any – do you have a sense for how the turnarounds are going at the Alecto hospitals so far?

Yes, they are all doing well. The one facility in Dallas we had projected it to be I say Dallas, it’s up in Sherman, its north of there. We had projected that it would be slower than the others and it is on that track, but all of them are right on schedule for what our original projections were.

Great, thank you.

Thank you. The next question comes from the line of Tayo Okusanya of Jefferies.

George Hoglund on for Tayo. I was just wondering also if you can talk about potential returns or cap rates on the pipeline. I don’t know if I caught this or missed this earlier, but would you expect things to be in line with recent transactions or any recent trends in cap rates you could comment on?

Yes, George, that’s certainly a fair question with interest rates coming down, but everything that we are looking at right now is still in that range that we have said over the last few quarters.

Okay, thanks. And anywhere in Europe sort of besides Germany that you guys are looking at?

Well, they certainly are. As we have always said and as we went into Europe is that it’s Western Europe, obviously not countries that we all would recognize as countries that we wouldn’t be in, but for a real general definition, it’s Western Europe.

Okay, alright. Thanks guys.

Thank you. The next question comes from Chad Vanacore of Stifel.

Hi, good morning.

Good morning.

Hey, so the MEDIAN deal you had originally thought that you would close by mid first quarter is the whole transaction closed now or are there a still couple of pieces left?

No, I think we originally said that we were hoping to close the initial phase of the transaction early to mid-first quarter. And in fact we closed that – that’s what we closed that on I think it was December 15. And so from that step having closed that then we go into executing sale leaseback contracts with each of the 40 operators, 40 subsidiary operators for the facilities that we intend to buy and then leaseback that then triggers the preemption right period that the local municipalities have which in general we expect 5 weeks to 6 weeks, but they can take longer. So having just given you that brief background, we still hope to close a substantial number of the sale leaseback transactions in the first quarter. But it could bleed over into the second quarter. So again right now, of the total €705 million transaction, we have invested €425 million. There is another €280 million in incremental investment to complete the sale-leaseback. We are earning on that €425 million now, substantially all of it. And then as we layer on the remainder of the purchase price for each respective facility we will begin earning on that. And again just to summarize, we still think most of that gets closed in the first quarter. But at this point there will probably be some bleed over into the second quarter period.

Alright, that’s great color. Thanks. And as far as you got – now got a huge chunk of your portfolio in Germany, do you have any boots on the ground there a team and office and then how that – how should we think about that affecting G&A?

Yes. Chad, so some of this is I addressed on the last call about where we think we are going to be with the G&A and our investments in Germany and in all of Europe. We don’t have any boots on the ground per se. What we do have is that we are using our Birmingham office and our New York office to handle all of that internally. We don’t have to manage the properties on a day-to-day basis, so it’s not like we need to be there on an everyday basis. We probably have more G&A expense now because of the way we are structuring it. But I think we are getting more benefit right now by having everybody in the same office and being able to communicate and collaborate better. There will come a time that we will have boots on the ground in Europe and when we do it will actually reduce our overall G&A.

Alright, I appreciate your time today. Thanks.

Thank you. The next question comes from Mr. Juan Sanabria of BoA.

Good morning guys.

Hi Juan, how are you doing?

Good. Thank you very much. Hope you guys are well. Just wondering if you could give a little color – more color on the wellness centers, their rental contribution I know you have some disclosure in the supp, maybe expectation that we should have on that rent going away or how we should be thinking about the sale process there?

Juan it’s such a small investment you won’t see it, net book value there is $10 million, that’s never been a large investment for us. You will remember that this was a tag along on a portfolio of properties that we bought. It is – it has contributed very little to additional rent. The total rent amount is about $1 million.

Okay. And then on the First Choice, how are those developments progressing, what’s left to kind of be put on track with regards to the CapEx you have committed to that agreement, that venture?

We currently have 28 facilities that are open or under construction. We have of the total commitment that we have made, we have approximately – we have about $70 million left to fund.

Okay. And any sense of how much got placed into service in the fourth quarter?

One property.

Okay. And just going back to the FX portion that I think Karin had. I know you kind of said it was early days for your modeling of this, but any sense of what the cash impact like a Fed impact to earnings would be for say a 10% swing in the euro versus the U.S. dollar? Any sort of sensitivities you could share?

Well, we haven’t modeled that, because again on a GAAP basis, I mean, it’s pretty easy probably because you know what our GAAP earnings are, our GAAP rent is on the German portfolios. From that, you would first of all subtract the euro-denominated interest that we pay out of those earnings. And of course that number is undetermined now, because we haven’t concluded how we are going to finance those and what the cost will be. And then that basically that net is subject to a GAAP adjustment from quarter-to-quarter based directly on the exchange rate. So, if the exchange rate moved against us by 10%, basically take that 10% move and apply it to that quarter’s income, that quarter’s net income that I have just described. So, again for those reasons, we don’t know what that would be. We – and then again that’s the GAAP impact. The cash economic impact will be reduced even further substantially frankly, because we will keep in Europe the funds that we want to reinvest there. And as Ed said and we have made clear we will continue to be active in Europe. We don’t have any large transactions that are in the pipeline right now, but they will be funded to the extent we can from European cash flows. So, that’s – those are some of the components that go into, if you were trying to predict, they will be pretty big assumptions to make, but that’s the process.

So, Juan, on an economic basis, where we are right now if you over – get past the investment side of getting money over there, it’s really a relatively small amount of dollar risk or euro risk right now, because of what Steve just described of the interest that we are paying and the reinvestments that we are making in Europe. So, it’s not an issue right now.

Okay, thanks for the color.

The next question comes from Michael Carroll of RBC.

You described how you would get to the bottom end and the top end of your FFO run-rate, is that mostly FX potential changes?

No, it’s not. The FX is kind of built into that. It for the most part is – the biggest component by far would be the difference in interest cost of really two components. One, number one, do we use secured or unsecured, okay? And Karin asked and we talked about the spread between those two. And then secondly is on a long-term basis, what our overall capital structure will look like whether we are using more or less relative equity? And what we have said from the beginning, but for many years frankly and then reiterated as we did this MEDIAN transaction was we will revert to our long-term goals of 40% to 45% total leverage and 5 to 5.5 times debt to EBITDA. And so that again that describes the great majority of the variance in the range of run-rate.

Okay, great. And then could you remind us the status of the lease expirations in 2015?

Just a second, Mike.

In 2015, we only had the two properties that we have been discussing since last year, the two CHS South Carolina properties, which is a total of about $35 million.

What’s the – are you negotiating leases or are you planning on selling those assets, is there any update on this?

Well, the update was that we are negotiating with someone right now and we hope to have further information that we can provide later in this quarter.

And that would be as a new operator, not as a sale of the properties.

Okay. And then my last question is related, can you give us any updated color on the LTAC patient criteria and how it could impact your portfolio? I think my sense is, is that the good assets will win and the bad assets might see some pressure. I mean, how does your portfolio stack up against that and particularly how is the Ernest assets?

Yes. The Ernest assets, we think will do exceptionally well. We think that overall our portfolio would do well. We have constant conversations with our existing operators about their existing portfolio within our portfolio. All of them believe that long-term this will be a good benefit for all of our facilities. And we think you are exactly right, the facilities that generate – that perform well with the better operators that have higher acuity patients will do very well under this scenario.

Okay, great. Thanks.

The next question comes from Karin Ford of KeyBanc Capital Markets.

Hi. I just wanted to follow-up on that last question from Mike. So Steve, you are saying that the bottom end of the guidance would potentially contemplate additional equity, since it looks like you guys are sort of at the top end of year range pro forma following the equity deal?

Well, on a long-term basis, that would be part of it. Most of – most of it though would be on the bottom end if we would go with the higher cost debt, which at this time still would or at least marginally look like to be unsecured.

Okay. And then just last question, can you just give us some help on what a good run rate might be for G&A, is it the 11.4, you did in the fourth quarter or something lower than that?

That’s a very good question, Karin. In the fourth quarter, there were a couple of – I am not going to call them one-time, but there are only – there are periodic increases. The most of the difference between say the first quarter – I mean fourth quarter and third quarter is in recruiting and compensation. So – and the other is made up primarily of some of the international cost, especially the early international costs that are related to the MEDIAN transaction. On recruiting and compensations about a $1.6 million difference between the third quarter and fourth quarters. And that’s primarily related to share grants and sign-on payments, relocation benefits and placement fees for two new higher level acquisitions people that are now going to be reporting to Frank in New York. And then to a lesser extent to the true up of our performance measures that our long-term share grants are based on. It doesn’t result in any additional compensation or any additional share grants. It just accelerates the vesting time because we exceeded those performance levels. So that’s just by way of explanation of the higher G&A in the fourth quarter. Going forward, we think it’s a pretty good quarterly run rate if you were to assume in the $10.5 million quarterly range.

Thank you very much.

Thank you for your question. I would now like to turn the call over to Ed Aldag for closing remarks.

Cathy, thank you very much and as always we appreciate your interest in MBT and listing it on the call. If you have any further questions, don’t hesitate to call myself, Steve, Charles Lambert or Tim Berryman. Thank you very much.